Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04985032 · ClinicalTrials.gov registry record

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

A clinical trial of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast, sponsored by RPCR.

Recruiting
Registry status
200
Enrollment target
2
Study locations

NCT04985032 is a study of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast that is actively recruiting participants, run by RPCR. The registered enrollment target is 200 participants, below the 244-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04985032, a study of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast, is actively recruiting participants, sponsored by RPCR.

RECRUITING
Registry status
200 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years

Interventions

  • RADIATION stereotactic body radiation therapy

Study Locations (2)

Florida

  • CyberKnife Center of South Florida in Stuart - Stuart
  • CyberKnife Centers of Tampa Bay - Tampa

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-08-15
Est. Completion 2027-06

Sponsor

RPCR

1 total trials

What the Registry Record Tells You About NCT04985032

The ClinicalTrials.gov registry entry for NCT04985032 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (18% lower). The listed sponsor is RPCR, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 1 intervention - of which stereotactic body radiation therapy is the first listed.

NCT04985032 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04985032 about?

NCT04985032 is a clinical study titled "Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)". This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respirat...

What is the current status of trial NCT04985032?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-08-15. Estimated completion is 2027-06.

What conditions does trial NCT04985032 study?

This clinical trial studies the following conditions: Ductal Carcinoma In Situ, Invasive Ductal Carcinoma of Female Breast.

What interventions are being tested in trial NCT04985032?

The interventions under investigation include: stereotactic body radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT04985032?

This trial is sponsored by RPCR, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04985032 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ductal Carcinoma In Situ

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.